Bristol Myers Squibb announced positive topline results from the phase 3 CheckMate -648 trial evaluating treatment with Opdivo (nivolumab) plus chemotherapy or Opdivo plus Yervoy (ipilimumab) in ...
a per BICR; b Evaluated in responders. ORR, objective response rate; m, median. This is an ASCO Meeting Abstract from the 2023 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results